The competitive PDPK1 inhibitor and orphan drug OSU-03012 (AR-12) was another targeted drug with lineage specificity (Fig. 5e), where our results indicated excellent sensitivity in most T-ALL cell lines and in a subset of BCP-ALL cell lines. Here, PDPK1 is linked to acute lymphoblastic leukemia.